https://www.biopharmawatch.com/news/MRNA/moderna-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-06T00:00:00.000Z Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 https://www.biopharmawatch.com/news/CLPT/clearpoint-neuro-announces-third-quarter-results-2026 BiopharmaWatch en 2026-10-28T00:00:00.000Z ClearPoint Neuro to Announce Third Quarter 2026 Results October 28, 2026 https://www.biopharmawatch.com/news/BHVN/biohaven-oral-presentation-asn-kidney-week-2026-spotlights-bhv-1420 BiopharmaWatch en 2026-10-26T11:30:00.000Z Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy https://www.biopharmawatch.com/news/BHVN/biohaven-bhv-1420-asn-kidney-week-2026 BiopharmaWatch en 2026-10-26T11:30:00.000Z Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy https://www.biopharmawatch.com/news/CGC/canopy-growth-2026-annual-meeting-results BiopharmaWatch en 2026-10-26T11:30:00.000Z Canopy Growth Announces Results of 2026 Annual General and Special Meeting of Shareholders https://www.biopharmawatch.com/news/DAVI/davion-healthcare-acquisition-humaskan-medical-technology BiopharmaWatch en 2026-10-26T11:30:00.000Z Davion Healthcare Announces US$25 Million Acquisition of Humaskan Medical Technology IP https://www.biopharmawatch.com/news/BWAY/brainsway-expands-insurance-coverage-deep-tms-ocd BiopharmaWatch en 2026-10-26T11:30:00.000Z BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives https://www.biopharmawatch.com/news/MDCX/medicus-pharma-regains-nasdaq-compliance BiopharmaWatch en 2026-10-26T11:30:00.000Z Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-first-patient-dosed-xtx501-trial BiopharmaWatch en 2026-10-26T11:30:00.000Z Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC https://www.biopharmawatch.com/news/IMRX/immuneering-phase-3-mapkeeper-301-trial-esmo-2026 BiopharmaWatch en 2026-10-26T11:30:00.000Z Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026 https://www.biopharmawatch.com/news/MGNX/macrogenics-positive-phase-2-linnet-results-lorigerlimab BiopharmaWatch en 2026-10-26T11:06:00.000Z MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer https://www.biopharmawatch.com/news/REGN/regeneron-barda-agreement-inmazeb-ebola-treatment BiopharmaWatch en 2026-10-26T11:00:00.000Z Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness https://www.biopharmawatch.com/news/REGN/regeneron-barda-agreement-ebola-treatment-inmazeb BiopharmaWatch en 2026-10-26T11:00:00.000Z Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness https://www.biopharmawatch.com/news/NTRA/natera-asn-kidney-week-2026-genetic-testing-renasight BiopharmaWatch en 2026-10-26T11:00:00.000Z Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™ https://www.biopharmawatch.com/news/ENTA/enanta-resolve-phase-2b-3-zelicapavir-rsv BiopharmaWatch en 2026-10-26T11:00:00.000Z Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV) https://www.biopharmawatch.com/news/IMNM/immunome-varegacestat-esmo-2026-data BiopharmaWatch en 2026-10-26T11:00:00.000Z Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026 https://www.biopharmawatch.com/news/GMAB/genmab-phase-2-data-petosemtamab-pembrolizumab-hnscc BiopharmaWatch en 2026-10-26T11:00:00.000Z Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma https://www.biopharmawatch.com/news/FATE/fate-therapeutics-ft819-lupus-nephritis-asn-kidney-week-2026 BiopharmaWatch en 2026-10-26T11:00:00.000Z Fate Therapeutics Presents Updated Preliminary Data for FT819 in Active Lupus Nephritis at American Society of Nephrology Kidney Week 2026 https://www.biopharmawatch.com/news/PLUR/pluri-zeo-partner-us-manufacturing-regenerative-medicine BiopharmaWatch en 2026-10-26T11:00:00.000Z Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-orka-001-results-everlast-b-trial BiopharmaWatch en 2026-10-26T11:00:00.000Z Oruka Therapeutics Announces Positive Week 16 Results for ORKA-001 from the Ongoing EVERLAST-B Trial in Moderate-to-Severe Psoriasis https://www.biopharmawatch.com/news/ELDN/eledon-phase-2-bestow-trial-data-kidney-week-2026 BiopharmaWatch en 2026-10-26T11:00:00.000Z Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting https://www.biopharmawatch.com/news/HROW/harrow-third-quarter-2026-financial-results BiopharmaWatch en 2026-10-26T11:00:00.000Z Harrow To Report Third Quarter 2026 Financial Results After Market Close on November 9, 2026 https://www.biopharmawatch.com/news/ABOS/acumen-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-10-26T11:00:00.000Z Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/IOVA/iovance-lifileucel-esmo-2026-data BiopharmaWatch en 2026-10-26T11:00:00.000Z Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026 https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-q3-2026-results-call BiopharmaWatch en 2026-10-26T11:00:00.000Z Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/SNDX/syndax-announces-q3-2026-results-conference-call BiopharmaWatch en 2026-10-26T11:00:00.000Z Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026 https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-eik1001-esmo-2026 BiopharmaWatch en 2026-10-26T10:00:00.000Z Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress https://www.biopharmawatch.com/news/MDLN/medline-10-years-partnership-wrap-responsible-manufacturing BiopharmaWatch en 2026-10-26T09:00:00.000Z Medline Celebrates 10 Years of Partnership with WRAP, Advancing Responsible Manufacturing https://www.biopharmawatch.com/news/BNTX/biontech-dualitybio-dynasty-breast02-trial-results BiopharmaWatch en 2026-10-26T09:00:00.000Z BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer https://www.biopharmawatch.com/news/HCM/hutchmed-sanovo-phase-iii-orpathys-tagrisso-lung-cancer BiopharmaWatch en 2026-10-26T08:30:00.000Z HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026 https://www.biopharmawatch.com/news/YI/111-inc-appoints-independent-advisors-special-committee BiopharmaWatch en 2026-10-26T08:00:00.000Z 111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-fda-litigation-update BiopharmaWatch en 2026-10-26T08:00:00.000Z Phathom Pharmaceuticals Provides Update on FDA Litigation https://www.biopharmawatch.com/news/BMY/iza-bren-doubles-pfs-egfr-nsclc-study BiopharmaWatch en 2026-10-26T07:30:00.000Z Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study https://www.biopharmawatch.com/news/BMY/iza-bren-doubles-pfs-nsclc-study BiopharmaWatch en 2026-10-26T07:30:00.000Z Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-10-26 BiopharmaWatch en 2026-10-26T07:15:24.500Z IGALMI PDUFA for Agitation: Biotech Catalysts Oct 26, 2026 https://www.biopharmawatch.com/news/HCM/hutchmed-saffron-phase-iii-trial-results BiopharmaWatch en 2026-10-26T00:00:00.000Z HUTCHMED Highlights SAFFRON Global Phase III Data Presented at ESMO Congress 2026 and Simultaneously Published in The New England Journal of Medicine https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-host-conference-call-report-week-16-data-orka BiopharmaWatch en 2026-10-25T16:00:00.000Z Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 https://www.biopharmawatch.com/news/SMMT/ivonescimab-chemotherapy-advanced-biliary-tract-cancer BiopharmaWatch en 2026-10-25T15:52:00.000Z Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China https://www.biopharmawatch.com/news/JNJ/rybrevant-faspro-amivantamab-hyaluronidase-lpuj-combination-demonstrates-77-overall BiopharmaWatch en 2026-10-25T13:45:00.000Z RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer https://www.biopharmawatch.com/news/JNJ/rybrevant-faspro-head-neck-cancer-response-rate BiopharmaWatch en 2026-10-25T13:45:00.000Z RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer https://www.biopharmawatch.com/news/AVBP/arrivent-phase-1-data-cdh17-targeted-adc-arr-217 BiopharmaWatch en 2026-10-25T13:00:00.000Z ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 https://www.biopharmawatch.com/news/AMRN/amarin-update-phase-3-epa-metastasis-trial-emt2 BiopharmaWatch en 2026-10-25T12:11:00.000Z Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM) https://www.biopharmawatch.com/news/AGEN/agenus-phase-2-results-neoasiss-study BiopharmaWatch en 2026-10-25T11:00:00.000Z Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026 https://www.biopharmawatch.com/news/GMAB/genmab-phase-2-study-petosemtamab-colorectal-cancer BiopharmaWatch en 2026-10-25T11:00:00.000Z Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer https://www.biopharmawatch.com/news/NBP/novabridge-biosciences-givastomig-phase-1b-data-esmo-2026 BiopharmaWatch en 2026-10-25T11:00:00.000Z NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development https://www.biopharmawatch.com/news/REGN/libtayo-cemiplimab-survival-benefit-cscc BiopharmaWatch en 2026-10-25T09:15:00.000Z Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) https://www.biopharmawatch.com/news/XNCR/xencor-phase-1-xmab819-clear-cell-renal-cancer BiopharmaWatch en 2026-10-25T08:35:00.000Z Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors https://www.biopharmawatch.com/news/LLY/lilly-olomorasib-esmo-2026-data BiopharmaWatch en 2026-10-25T07:30:00.000Z New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer https://www.biopharmawatch.com/news/JNJ/jnj-6143-prostate-cancer-phase-1-results BiopharmaWatch en 2026-10-25T07:30:00.000Z Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule https://www.biopharmawatch.com/news/BNTX/biontech-bristol-myers-squibb-pumitamig-phase-2-data BiopharmaWatch en 2026-10-25T07:30:00.000Z BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy https://www.biopharmawatch.com/news/CLYM/climb-bio-budoprutug-phase-2-data-asn-kidney-week-2026 BiopharmaWatch en 2026-10-24T23:30:00.000Z Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026 https://www.biopharmawatch.com/news/PFE/pfizer-25-valent-pneumococcal-vaccine-phase-2-results BiopharmaWatch en 2026-10-24T15:18:00.000Z Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026 https://www.biopharmawatch.com/news/AMGN/imdelltra-imfinzi-small-cell-lung-cancer-results BiopharmaWatch en 2026-10-24T14:30:00.000Z IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER https://www.biopharmawatch.com/news/JNJ/apalutamide-reduces-recurrence-risk-prostate-cancer BiopharmaWatch en 2026-10-24T13:01:00.000Z Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer https://www.biopharmawatch.com/news/JNJ/johnson-johnson-announces-erleada-apalutamide-treatment-surgery-reduces-risk-recurrence BiopharmaWatch en 2026-10-24T12:54:00.000Z Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer https://www.biopharmawatch.com/news/PBLS/parabilis-medicines-zolucatetide-phase-1-2-data BiopharmaWatch en 2026-10-24T12:45:00.000Z Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors